← All candidates
45 insider filings on record.
45 filings on record.
TARSTarsus Pharmaceuticals, Inc.
NasdaqGS · Healthcare · $3.66B
$78.23
-2.15% · Sep 15
45 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 25 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.66B
Float
32.7M
70% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
32.4
Price / sales
6.0
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
40 more transactions on Pro →Context
Wall St
$94.11 avg target
+20.3% vs today · 9 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.16 act+$0.26
Q4 '25−$0.20 act−$0.21
Q3 '25−$0.30 act+$0.03
Q2 '25−$0.48 act−$0.12
Coverage
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to BuyZacks · 07-08Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?Zacks · 07-03TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits · 07-01Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares FallMT Newswires · 07-01
The file stays open
45 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice